TabsDetailsBasic DetailsDate Posted: Sunday, January 15, 2012Status: CompleteMedical Product: bupropion, vareniclineHealth Outcome(s): acute coronary occlusion without myocardial infarctionacute myocardial infarction (AMI)cardiovascular outcomeintermediate coronary syndromeunstable anginaDescription: Modular program-based one-time assessment of the risk of a composite cardiovascular outcome associated with new use of smoking cessation drugs, including varenicline and bupropion. Modular programs are adaptable standardized programs. Read More Deliverables (1)Mini-Sentinel Smoking Cessation Drugs and Selected Cardiovascular OutcomesAdditional InformationAdditional DetailsFDA Center: CDERStudy Type: Modular ProgramAssessment Type: Safety AnalysesData Sources: Mini-Sentinel Distributed Database (MSDD)Related Links: Rapid Assessment of Cardiovascular Risk Among Users of Smoking Cessation Drugs Within the US Food and Drug Administration's Mini-Sentinel Program
